Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.200
-0.090 (-2.10%)
Mar 10, 2026, 4:00 PM EDT - Market closed
Aquestive Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Aquestive Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $9.00, which forecasts a 114.29% increase in the stock price over the next year. The lowest target is $7.00 and the highest is $12.
Price Target: $9.00 (+114.29%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 7, 2025.
Analyst Ratings
The average analyst rating for Aquestive Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $5 → $8 | Buy | Maintains | $5 → $8 | +90.48% | Nov 7, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $9 → $12 | Buy | Maintains | $9 → $12 | +185.71% | Oct 9, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $7 → $8 | Buy | Maintains | $7 → $8 | +90.48% | Sep 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +138.10% | Jun 17, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $15 → $7 | Buy | Initiates | $15 → $7 | +66.67% | Jun 2, 2025 |
Financial Forecast
Revenue This Year
50.89M
from 44.55M
Increased by 14.23%
Revenue Next Year
80.58M
from 50.89M
Increased by 58.36%
EPS This Year
-0.59
from -0.78
EPS Next Year
-0.41
from -0.59
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 77.9M | 136.1M | |||
| Avg | 50.9M | 80.6M | |||
| Low | 37.2M | 50.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 74.8% | 167.5% | |||
| Avg | 14.2% | 58.4% | |||
| Low | -16.4% | -1.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | -0.27 | -0.09 | ||
| Avg | -0.59 | -0.41 | ||
| Low | -0.78 | -0.57 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.